Skip to content
Study details
Enrolling now

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

University of Chicago
NCT IDNCT06207123ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

15

Study length

about 2.2 years

Ages

18+

Locations

2 sites in IL, NY

About this study

This trial is testing a treatment called LP-118 with other medicines like ponatinib, vincristine, and dexamethasone in people whose leukemia has returned after treatment or hasn't responded to previous treatments. The goal is to find out if LP-118 can be used safely along with these other medications.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Dexamethasone
  • 2.Take LP-118
  • 3.Take Methotrexate
  • +2 more
PhasePhase 1/Phase 2
DrugDexamethasone
Routeinjection

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

dexamethasone, methotrexate, ponatinib, vincristine

Drug routes

injection, ocular, oral (Oral Tablet)

Endpoints

Secondary: Complete Clinical Remission (CR) with Measurable Residual Disease (MRD), Overall Survival, Progression-Free Survival

Body systems

Oncology